DMIIU · Drugs Made In America Acquisition II Corp. Ordinary Shares

Drugs Made In America Acquisition II Corp. (DMII) reported Q1 2026 results consistent with its pre-business combination SPAC operations, where non-operating income from trust account interest generated net profitability despite ongoing operating losses. Net income reached $4.3 million, primarily because interest earned on cash and investments held in the trust—typically in government treasury obligations or cash equivalents—outpaced the $132 thousand operating loss. This dynamic underscores the SPAC model's reliance on investment returns to offset administrative overhead during the search for a pharmaceutical target, without drawing down trust assets for operations.

The operating loss of $132 thousand stems from general and administrative expenses associated with maintaining public company status and conducting due diligence on potential acquisitions. These costs are routine for a SPAC in its pre-combination phase, where no revenue is generated from operations. Similarly, net cash provided by operating activities showed a use of $103 thousand, largely due to non-cash adjustments for the interest income and small working capital fluctuations. This cash burn highlights the non-cash nature of the period's profitability, with actual liquidity needs met through existing cash balances rather than operational cash generation.

Looking ahead, management acknowledges ongoing challenges. The company expects to incur significant professional costs to sustain public trading status and substantial transaction expenses in pursuing an initial business combination. A going concern doubt is flagged due to these anticipated outlays, with success hinging on identifying and closing a suitable pharma acquisition. While current liquidity supports short-term needs, the absence of revenue and dependence on sponsor support elevate execution risk. Investors should monitor progress toward combination within the available timeframe, as failure could lead to liquidation.